Background: Currently there are major efforts to develop strategies for the in vivo imaging of
pancreatic beta cell mass as a clinical and investigational tool for detecting and tracking the …

The increasing incidence of diabetes requires a better understanding of the pathogenesis of
the clinical disease. Studies in prevention and treatment have been hampered by the single …

Diabetes mellitus results in impaired insulin production by pancreatic beta-cells due to their
death and/or dysfunction. There is a growing unmet need among diabetes researches and …

Visualization and quantification of the native β‐cell mass in vivo in humans appear to be
important in the study of the natural course of diabetes, and in ongoing trials aimed at …

The β-cell loss seen in diabetes mellitus could be monitored clinically by positron emission
tomography (PET) if imaging agents were sufficiently specific for β-cells to overcome the …

Diabetes mellitus is a growing worldwide epidemic disease, currently affecting 1 in 12
adults. Treatment of disease complications typically consumes∼ 10% of healthcare budgets …

Since diabetes is becoming a global epidemic, there is a great need to develop early β-cell
specific diagnostic techniques for this disorder. There are two types of diabetes (ie, type 1 …

At present, the onset and progress of diabetes, and the efficacy of potential treatments, can
only be assessed through indirect means, ie blood glucose, insulin, or C‐peptide …

Pancreatic β-cell mass (BCM) is a major determinant of the quantity of insulin that can be
secreted. BCM is markedly reduced in type 1 diabetes because of selective autoimmune …

Glucose-stimulated insulin secretion (GSIS) from pancreatic beta-cells is critical to the
maintenance of blood glucose homeostasis in animals. Both decrease in pancreatic beta …